|
nasopharyngeal carcinoma |
20 |
|
cancer susceptibility genes |
13 |
|
early-age onset |
13 |
|
mst1r |
13 |
|
whole-exome sequencing |
13 |
|
chinese |
12 |
|
children |
11 |
|
epstein-barr virus |
11 |
|
adolescent |
10 |
|
allergy |
10 |
|
asparaginase |
10 |
|
human leukocyte antigens |
10 |
|
hypersensitivity |
10 |
|
hepatoblastoma |
9 |
|
pediatric |
9 |
|
lytic cycle |
8 |
|
medical sciences |
8 |
|
oncology medical sciences |
8 |
|
pediatrics |
8 |
|
epstein–barr virus |
7 |
|
humans |
7 |
|
relapse |
7 |
|
retrospective studies |
7 |
|
treatment outcome |
7 |
|
polymerase chain reaction |
6 |
|
adult |
5 |
|
antigens, cd56 - metabolism |
5 |
|
apoptosis |
5 |
|
candida |
5 |
|
chinese children |
5 |
|
ebv‐encoded small rna |
5 |
|
genome‐wide analysis |
5 |
|
hematopoietic stem cell transplantation |
5 |
|
hepatitis b virus |
5 |
|
hepatocellular carcinoma |
5 |
|
immunophenotyping |
5 |
|
leukemia |
5 |
|
lytic reactivation |
5 |
|
nucleic acid amplification |
5 |
|
pretreatment extent of disease |
5 |
|
renal abscess |
5 |
|
risk stratification |
5 |
|
sequencing |
5 |
|
surveillance |
5 |
|
vaccination |
5 |
|
11c-acetate |
4 |
|
aged |
4 |
|
anti-bacterial agents - therapeutic use |
4 |
|
antigens, neoplasm - metabolism |
4 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
4 |
|
autoimmune diseases |
4 |
|
autoimmune diseases - epidemiology - ethnology |
4 |
|
autophagy |
4 |
|
bacterial infections - epidemiology - ethnology |
4 |
|
bone marrow transplantation |
4 |
|
carcinoma, hepatocellular - epidemiology - pathology |
4 |
|
cd56 |
4 |
|
chemotherapy |
4 |
|
child |
4 |
|
child, preschool |
4 |
|
chronic |
4 |
|
combined modality therapy |
4 |
|
congenital fibrosarcoma |
4 |
|
cord blood |
4 |
|
cyclosporin |
4 |
|
disease progression |
4 |
|
donor lymphocyte infusion |
4 |
|
ebv |
4 |
|
epithelial cancer |
4 |
|
epstein-barr virus (ebv) |
4 |
|
female |
4 |
|
graft versus tumor effect |
4 |
|
haploidentical |
4 |
|
haploidentical hematopoietic stem cell transplantation |
4 |
|
hepatic artery ligation |
4 |
|
hepatoblastoma - epidemiology - pathology |
4 |
|
histone deacetylase inhibitor |
4 |
|
hong kong - epidemiology |
4 |
|
hospitalization - statistics & numerical data |
4 |
|
immune thrombocytopenia |
4 |
|
immunoglobulins |
4 |
|
immunotherapy |
4 |
|
intestinal |
4 |
|
killer cells, natural - pathology |
4 |
|
klebsiella infections - complications - drug therapy - epidemiology |
4 |
|
klebsiella pneumoniae - drug effects |
4 |
|
leukoencephalopathy |
4 |
|
liver neoplasms - epidemiology - pathology |
4 |
|
liver tumors |
4 |
|
lymphoma, non-hodgkin - diagnosis - drug therapy - radiotherapy |
4 |
|
lymphoma, t-cell, peripheral - diagnosis - drug therapy - radiotherapy |
4 |
|
lytic induction therapy |
4 |
|
male |
4 |
|
metastasis |
4 |
|
methotrexate |
4 |
|
middle aged |
4 |
|
nasopharyngeal carcinoma (npc) |
4 |
|
natural killer cell lymphoma/leukaemia |
4 |
|
neuroblastoma |
4 |
|
neurological complications |
4 |
|
neutropenia |
4 |
|
neutropenia - epidemiology - ethnology |
4 |
|
nose neoplasms - diagnosis - drug therapy - radiotherapy |
4 |
|
positron emission tomography |
4 |
|
posterior reversible encephalopathy syndrome |
4 |
|
prognosis |
4 |
|
rare tumor |
4 |
|
recurrence |
4 |
|
rhabdomyosarcoma |
4 |
|
rhabdomyosarcoma - mortality - pathology - therapy |
4 |
|
romidepsin |
4 |
|
soft tissue neoplasms - mortality - pathology - therapy |
4 |
|
thalassemia - complications |
4 |
|
total body irradiation |
4 |
|
transarterial embolization |
4 |
|
transplant-related morbidity |
4 |
|
tumor markers, biological - metabolism |
4 |
|
tumor rupture |
4 |
|
acinic cell carcinoma |
3 |
|
aplastic anaemia |
3 |
|
atp-binding cassette transporters - analysis |
3 |
|
autologous |
3 |
|
beta 2-microglobulin - analysis |
3 |
|
beta-thalassemia |
3 |
|
cancer treatment |
3 |
|
case report |
3 |
|
cerebral thrombosis |
3 |
|
childhood acute lymphoblastic leukaemia |
3 |
|
childhood cancer |
3 |
|
chimerism |
3 |
|
diabetes insipidus |
3 |
|
dysarthria |
3 |
|
embryonal sarcoma |
3 |
|
epidemiology |
3 |
|
epstein-barr virus infections - immunology |
3 |
|
fanconi anaemia |
3 |
|
formalin |
3 |
|
fungal infection |
3 |
|
gastric carcinoma |
3 |
|
genetic variation |
3 |
|
haematopoietic stem cell transplant |
3 |
|
hearing loss |
3 |
|
hemorrhagic cystitis |
3 |
|
hepatitis |
3 |
|
herpesvirus |
3 |
|
herpesvirus 4, human - classification - genetics - isolation & purification |
3 |
|
histocompatibility antigens class i - analysis |
3 |
|
hla class 1,immune escape |
3 |
|
immunodeficiency |
3 |
|
immunohistochemistry |
3 |
|
infectious mononucleosis |
3 |
|
interleukin 12 |
3 |
|
interleukin-10 |
3 |
|
interleukin-10 - analysis |
3 |
|
intrathecal |
3 |
|
iron chelation |
3 |
|
iron chelator |
3 |
|
jmml |
3 |
|
juvenile pernicious anaemia |
3 |
|
l-asparaginase |
3 |
|
liver tumour |
3 |
|
long-term complications |
3 |
|
lymphocyte transfusion |
3 |
|
lymphoma, t-cell - immunology |
3 |
|
magnetic resonance imaging |
3 |
|
mesenchymal hamartoma |
3 |
|
monosomy 7 |
3 |
|
myeloperoxidase deficiency |
3 |
|
nasal nk/t-cell lymphoma |
3 |
|
nasopharyngeal neoplasms - virology |
3 |
|
natural killer cells |
3 |
|
neurofibromatosis |
3 |
|
nose neoplasms - immunology |
3 |
|
prematurity |
3 |
|
quality of life |
3 |
|
questionnaires |
3 |
|
rhizopus |
3 |
|
salivary gland |
3 |
|
second cancer |
3 |
|
selective iga deficiency |
3 |
|
suberoylanilide hydroxamic acid |
3 |
|
t cell dysfunction |
3 |
|
tap 1 |
3 |
|
thalassemia - therapy |
3 |
|
transplantation |
3 |
|
transplantation, homologous |
3 |
|
vitiligo |
3 |
|
von willebrand disease |
3 |
|
wiskott-aldrich syndrome |
3 |
|
zygomycosis |
3 |
|
β2-microglobulin |
3 |
|
abdominal distension |
2 |
|
acute megakaryoblastic leukaemia (amkl) |
2 |
|
allogeneic hematopoietic stem cell transplantation |
2 |
|
allopurinol - therapeutic use |
2 |
|
angiogenesis |
2 |
|
antigens, cd - analysis |
2 |
|
antigens, cd2 - analysis |
2 |
|
antigens, cd3 - analysis |
2 |
|
antigens, cd56 |
2 |
|
antigens, differentiation, t-lymphocyte - analysis |
2 |
|
antigens, viral - genetics |
2 |
|
antimetabolites - therapeutic use |
2 |
|
asymptomatic primary infection |
2 |
|
autologous hematopoietic stem cell transplantation |
2 |
|
b cell lymphoma |
2 |
|
b lymphocyte |
2 |
|
beta-thalassemia - complications - drug therapy |
2 |
|
beta-thalassemia - diagnosis - drug therapy |
2 |
|
blf4 gene |
2 |
|
bllf1 gene |
2 |
|
bllf2 gene |
2 |
|
bolf1 gene |
2 |
|
brain tumor |
2 |
|
burkitt lymphoma |
2 |
|
cancer chemotherapy |
2 |
|
cardiac magnetic resonance imaging t2* (mri t2*) |
2 |
|
cardiac t2* |
2 |
|
carrier state |
2 |
|
case series |
2 |
|
cd4-cd8 ratio |
2 |
|
cd8+ t lymphocyte |
2 |
|
cell cycle |
2 |
|
chelation protocol |
2 |
|
chelation therapy - methods |
2 |
|
chickenpox vaccine - therapeutic use |
2 |
|
combined therapy |
2 |
|
controlled clinical trials as topic |
2 |
|
cytokines |
2 |
|
cytotoxic cell antigen |
2 |
|
deferasirox |
2 |
|
deferiprone (l1) |
2 |
|
deferoxamine (dfo) |
2 |
|
deferoxamine(dfo) |
2 |
|
dendritic cell |
2 |
|
diagnosis |
2 |
|
diarrhea |
2 |
|
dna, neoplasm - genetics |
2 |
|
dna-binding proteins - biosynthesis - genetics |
2 |
|
down syndrome |
2 |
|
dural sinus thrombosis |
2 |
|
epithelium - virology |
2 |
|
epstein-barr virus nuclear antigen (ebna)-3c |
2 |
|
epstein-barr virus nuclear antigens - biosynthesis - genetics |
2 |
|
ferritins - blood |
2 |
|
gastrointestinal |
2 |
|
gene deletion |
2 |
|
gene expression |
2 |
|
gene rearrangement |
2 |
|
gene rearrangement, b-lymphocyte, heavy chain |
2 |
|
gene rearrangement, gamma-chain t-cell antigen receptor |
2 |
|
gene rearrangement, t-lymphocyte |
2 |
|
gene transcription |
2 |
|
genes, viral |
2 |
|
genes, viral - genetics |
2 |
|
genotype |
2 |
|
graft-versus-host disease |
2 |
|
growth factor receptor |
2 |
|
heart diseases - diagnosis - etiology - prevention and control |
2 |
|
hematologic neoplasms - complications |
2 |
|
herpesvirus 4, human |
2 |
|
herpesvirus 4, human - genetics |
2 |
|
herpesvirus 4, human - genetics - metabolism - physiology |
2 |
|
herpesvirus 4, human - isolation & purification |
2 |
|
hodgkin disease - pathology - virology |
2 |
|
immunodominance |
2 |
|
immunodominance hierarchies |
2 |
|
in situ hybridization |
2 |
|
infliximab |
2 |
|
influenza vaccines - therapeutic use |
2 |
|
interferon gamma |
2 |
|
interleukin 10 |
2 |
|
iron chelating agents - administration and dosage - therapeutic use |
2 |
|
iron chelating agents - therapeutic use |
2 |
|
iron overload |
2 |
|
iron overload - drug therapy |
2 |
|
juvenile myelomonocytic leukaemia |
2 |
|
killer cells, natural |
2 |
|
killer cells, natural - cytology - immunology - virology |
2 |
|
killer cells, natural - immunology |
2 |
|
killer cells, natural - immunology - pathology |
2 |
|
killer cells, natural - pathology - virology |
2 |
|
leukocytes, mononuclear - virology |
2 |
|
lymphoblastoid cells |
2 |
|
lymphoid tissue - virology |
2 |
|
lymphoma - classification - immunology |
2 |
|
lymphoma - genetics - immunology - pathology |
2 |
|
lymphoma - immunology - pathology - virology |
2 |
|
lymphoma, extranodal nk-t-cell - pathology - therapy |
2 |
|
lymphoma, t-cell - genetics |
2 |
|
lymphoma, t-cell - genetics - immunology - pathology |
2 |
|
lymphoma, t-cell - genetics - immunology - pathology - virology |
2 |
|
lymphoma, t-cell - pathology - virology |
2 |
|
lymphoma, t-cell, peripheral - immunology - pathology - virology |
2 |
|
lytic and latent proteins |
2 |
|
magnetic resonance imaging - methods |
2 |
|
membrane glycoproteins - analysis |
2 |
|
membrane proteins - analysis |
2 |
|
nasal lymphomas |
2 |
|
nasopharyngeal neoplasms - pathology - virology |
2 |
|
necrosis |
2 |
|
neoplasm proteins - analysis |
2 |
|
neoplasm staging |
2 |
|
nk-cell lymphoma |
2 |
|
nkg2a |
2 |
|
nose - virology |
2 |
|
nose neoplasms - classification - immunology |
2 |
|
nose neoplasms - genetics - immunology - pathology |
2 |
|
nose neoplasms - genetics - immunology - pathology - virology |
2 |
|
nose neoplasms - genetics - virology |
2 |
|
nose/pathology |
2 |
|
npc |
2 |
|
perforin |
2 |
|
phenotype |
2 |
|
poliovirus vaccines - therapeutic use |
2 |
|
poly(a)-binding proteins |
2 |
|
polycythaemia vera |
2 |
|
polyfunctional t cells |
2 |
|
polymorphism, genetic - genetics |
2 |
|
polymorphism, restriction fragment length |
2 |
|
pore forming cytotoxic proteins |
2 |
|
post-transplant lymphoproliferative disorder |
2 |
|
proteins |
2 |
|
receptors, antigen, t-cell - analysis |
2 |
|
receptors, antigen, t-cell - genetics |
2 |
|
renal tubular dysfunction |
2 |
|
ribosomal proteins |
2 |
|
rna, messenger - genetics - metabolism |
2 |
|
rna, viral - analysis |
2 |
|
rna-binding proteins - analysis |
2 |
|
serum electrolyte |
2 |
|
serum ferritin (sf) |
2 |
|
serum ferritin(sf) |
2 |
|
steroid dependent |
2 |
|
steroid refractory |
2 |
|
susceptibility |
2 |
|
t-cell lymphoma |
2 |
|
t-cell receptor |
2 |
|
t-lymphocyte subsets - immunology |
2 |
|
t-lymphocytes - pathology - virology |
2 |
|
t-lymphocytes, cytotoxic - immunology - pathology - virology |
2 |
|
targeted therapy |
2 |
|
thalassemia |
2 |
|
tia- 1 |
2 |
|
trans-activators - biosynthesis - genetics |
2 |
|
transcription, genetic |
2 |
|
transient myeloproliferative disease |
2 |
|
transplant complication |
2 |
|
trisomy 21 |
2 |
|
tuberculosis |
2 |
|
tumor lysis syndrome - mortality - prevention and control |
2 |
|
urate oxidase - adverse effects - therapeutic use |
2 |
|
viral gastroenteritis |
2 |
|
viral matrix proteins - biosynthesis - genetics |
2 |
|
viral matrix proteins - genetics |
2 |
|
viral proteins |
2 |
|
virus diseases - prevention and control |
2 |
|
virus latency |
2 |
|
β-thalassaemia |
2 |
|
acute lymphoblastic leukaemia |
1 |
|
acute lymphoblastic leukemia |
1 |
|
airway obstruction |
1 |
|
anterior mediastinal mass |
1 |
|
antineoplastic agents - pharmacology |
1 |
|
apoptosis - drug effects |
1 |
|
asian continental ancestry group |
1 |
|
b-lymphocytes - virology |
1 |
|
bortezomib |
1 |
|
cancer hallmarks |
1 |
|
carcinoma - drug therapy - virology |
1 |
|
central nervous system |
1 |
|
children and adolescents |
1 |
|
class i histone deacetylase inhibitor |
1 |
|
clinical trials on targeted therapies |
1 |
|
complete resection |
1 |
|
dual-responsive fluorescent ebv probe |
1 |
|
ebna1 |
1 |
|
ebna1-targeting agent |
1 |
|
ebna3 |
1 |
|
ebv latency |
1 |
|
ebv-specific lytic inducer |
1 |
|
efs |
1 |
|
endemic burkitt lymphoma |
1 |
|
endoplasmic reticulum stress |
1 |
|
epstein–barr virus (ebv) |
1 |
|
gene expression profiling |
1 |
|
genetic predisposition to disease |
1 |
|
hematology |
1 |
|
herpesvirus 4, human - drug effects |
1 |
|
herpesvirus 4, human - pathogenicity |
1 |
|
high grade b cell lymphoma |
1 |
|
histone deacetylase 6 |
1 |
|
histone deacetylase inhibitors - chemistry |
1 |
|
histone deacetylase inhibitors - pharmacology |
1 |
|
histone deacetylases - metabolism |
1 |
|
hodgkin lymphoma |
1 |
|
host-pathogen interactions |
1 |
|
incidence |
1 |
|
interhospital transport |
1 |
|
interleukin-12 - genetics - metabolism |
1 |
|
intraspinal hemorrhage |
1 |
|
latency |
1 |
|
lumbar puncture |
1 |
|
lymphoblastoid cell lines |
1 |
|
lymphoproliferative disease |
1 |
|
lymphoproliferative diseases |
1 |
|
lytic cycle reactivation |
1 |
|
lytic proteins |
1 |
|
marginal zone lymphoma |
1 |
|
mediastinal mass |
1 |
|
mycobacterium tuberculosis |
1 |
|
nasopharyngeal neoplasms - metabolism |
1 |
|
neurolymphomatosis |
1 |
|
neuropathy |
1 |
|
non-hodgkin lymphoma |
1 |
|
oncovirus |
1 |
|
osteonecrosis |
1 |
|
outcome |
1 |
|
pediatric lymphoma |
1 |
|
pediatric solid tumors |
1 |
|
peripheral neuropathy |
1 |
|
polymorphism, genetic |
1 |
|
postdural puncture headache |
1 |
|
precursor cell lymphoblastic leukemia-lymphoma |
1 |
|
proteasome endopeptidase complex - chemistry |
1 |
|
proteasome inhibitor |
1 |
|
refractory and relapsed non-hodgkin lymphoma |
1 |
|
risk factors |
1 |
|
rna, viral - genetics - metabolism |
1 |
|
saha |
1 |
|
stem cell transplant |
1 |
|
stem cell transplantation |
1 |
|
subdural hematoma |
1 |
|
superior vena cava obstruction |
1 |
|
survival |
1 |
|
survivin |
1 |
|
t(1;19) |
1 |
|
t-/nk-/b-cell non-hodgkin lymphoma |
1 |
|
tcf3-pbx1 |
1 |
|
transplant |
1 |
|
treatment |
1 |
|
viral-targeted strategies |
1 |
|
watch-and-wait |
1 |
|
young adult |
1 |
